Multiple Sclerosis, Relapsing-Remitting
Conditions
Keywords
Adherence, Persistence, Patient satisfaction
Brief summary
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
Interventions
Applied via the BETACONNECT device. Dose as prescribed by physician.
DEVICEBETACONNECT device
Used to apply Betaseron.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and females greater than or equal to 18 years of age * Diagnosis of RRMS according to revised McDonald Criteria (2010) or (CIS) * Prescribed BETASERON (note: decision to treat with BETASERON must be made independent of participation in this study) * Confirmation of insurance coverage for BETASERON treatment * Access to a personal computer to complete online patient satisfaction survey at Week 6
Exclusion criteria
* Currently enrolled in a clinical trial or other observational study for Multiple Sclerosis treatment * Documented substance abuse within the previous 6 months prior to study enrollment * Any major laboratory value abnormality that the investigator believes would preclude the patient from participating in the study * Any medical disorder, condition or history that in the opinion of the investigator would impair the patient's ability to participate in or complete the study * Pregnant or nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of BETASERON injections as captured by the BETACONNECT device | At 6 months |
| Time (days) between BETASERON injections as captured by BETACONNECT device | At 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Patient reported satisfaction by a questionnaire | At 6 weeks |
Countries
United States
Outcome results
None listed